Actively Recruiting
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery (MAGIPAC)
Led by University of Aarhus · Updated on 2026-04-29
200
Participants Needed
3
Research Sites
52 weeks
Total Duration
On this page
Sponsors
U
University of Aarhus
Lead Sponsor
R
Rigshospitalet, Denmark
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the added benefit of using magnetic resonance imaging (MRI) alongside computed tomography (CT) in diagnosing pancreatic cancer. This nationwide, prospective clinical trial aims to determine if MRI can better identify liver metastases in patients with pancreatic cancer to improve selection for surgery. The study is sponsored by the University of Aarhus and focuses on patients with locally resectable or borderline resectable tumors without liver metastases on CT. Participants will receive a preoperative MRI after their outpatient visit at the surgical clinic and before the scheduled surgery date. This diagnostic test is being evaluated to see if it changes treatment decisions compared to using CT alone. The study monitors patients through various timepoints including 1 week for treatment strategy changes and up to 3 years for survival and recurrence outcomes. During the study, participants undergo the MRI scan and are followed by researchers who assess treatment plans, surgical outcomes, survival rates, and healthcare costs. Key measurements include detection of liver metastases, surgery and resection rates within 1 month, and overall survival at 1 and 3 years. The total follow-up period extends to 3 years to track recurrence-free survival and long-term effects.
CONDITIONS
Brief Title
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
- No liver metastases on CT scan
- At least 18 years old and able to provide informed consent
- Expected pancreatic ductal adenocarcinoma based on CT scan
You will not qualify if you...
- Presence of metastatic disease
- Prior receipt of neoadjuvant chemotherapy or downstaging or downsizing treatment
- Comorbidity that makes major surgery impossible (inoperable)
- Lack of informed consent
- Unable to undergo MRI due to kidney insufficiency (eGFR < 60 ml/min/1.73 m2), claustrophobia, or cardiac pacemaker
- Postoperative histology not showing adenocarcinoma of pancreato-biliary origin
- MRI with liver-specific contrast already performed during standard workup
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 week
Participants undergo magnetic resonance imaging (MRI) in addition to computed tomography (CT) to detect liver metastases before surgery.
1 visit (in-person)
Duration - Up to 1 month
Participants undergo surgical resection based on imaging results and clinical assessment.
1 to 2 visits depending on surgical schedule
Duration - Up to 3 years
Participants are followed to assess overall survival, recurrence-free survival, and healthcare outcomes after surgery.
Periodic follow-up visits
Trial Site Locations
Total: 3 locations
1
Aalborg University Hospital
Aalborg, Denmark
Actively Recruiting
2
Aarhus University Hospital
Aarhus, Denmark, 8200
Actively Recruiting
3
Rigshospitalet
Copenhagen, Denmark
Actively Recruiting
Research Team
J
Jakob Kirkegård, MD, PhD
F
Frank Mortensen, MD, DMSc
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here